Glencore says long-term strategy may involve sale of Bunge stake
Glencore became the owner of the 16.4% stake after Bunge closed a long-delayed deal to merge with Glencore-backed grain handler Viterra in July, two years after announcing the $34 billion mega-deal.
"The agriculture business is not necessarily consistent with our business model," Glencore CEO Gary Nagle told a media call on Wednesday after the company released its first-half financial results. "Having a 16.4% shareholding in Bunge is probably not something that would be for Glencore in the long term."
He added that this did not mean Glencore would be in a rush to sell the stake, and if it ever decided to do that "we would do it in absolute collaboration and conjunction with Bunge, its board and its management".
The merger with Viterra enhanced Bunge's grain exporting and oilseed processing businesses in the United States and expanded Bunge's export capacity and physical grain storage and handling footprint in major wheat suppliers Canada and Australia, according to analysts.
Glencore's aim is to maximise the value of this investment, while the possible "exit of that at some stage in the future would be done very smartly and carefully to ensure that we preserve that value," the CEO added.
Glencore said on July 2 that its 16.4% stake in enlarged Bunge had a market value of $2.6 billion at the deal close, and that those shares were viewed by the miner as a surplus capital.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Sony to raise U.S. prices for all PlayStation 5 models
Sony Interactive Entertainment announced on Wednesday that it will increase the recommended retail prices for all PlayStation 5 models in the United States by $50, effective Thursday. The price adjustments are part of the company's response to what it described as a 'challenging economic environment.' The updated recommended retail prices are as follows: PlayStation 5 (standard): $549.99 (up from $499.99) PlayStation 5 Digital Edition: $499.99 (up from $449.99) PlayStation 5 Pro: $749.99 (up from $699.99) Sony confirmed that prices for PS5 accessories will remain unchanged. In April, Sony raised the PS5 prices by 10–15% in the U.K., Europe, Australia and New Zealand. In May, the company indicated that price hikes were under consideration to offset tariffs implemented by the Trump administration, according to The Verge. Sony's move mirrors wider industry trends: Microsoft raised prices on Xbox hardware and accessories earlier this year, and Nintendo also raised prices on its original Switch and upcoming accessories ahead of the Switch 2 launch. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Merck (MRK) Announces Positive Phase 3 Trial Results For KEYTRUDA In Bladder Cancer Treatment
Merck recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial promise to their oncology pipeline. Over the last quarter, Merck's shares increased by 4.44%, aligning with the broader market's upward trend, exemplified by the S&P 500 and Nasdaq Composite hitting all-time highs. While the company's advancements in KEYTRUDA applications and Health Canada's approval for cervical cancer treatment enhancement could have contributed positively, general market optimism associated with recent stability in inflation and expected Federal Reserve interest rate cuts likely added further weight. We've identified 1 possible red flag for Merck that you should be aware of. Uncover 14 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent positive topline results from Merck's Phase 3 KEYNOTE-905 trial could enhance the narrative around its strategic investments and new product launches. These developments may bolster Merck's leadership in oncology, potentially driving future revenue as KEYTRUDA applications expand. The efficacy in muscle-invasive bladder cancer strengthens their oncology pipeline, possibly counterbalancing challenges such as declining GARDASIL sales and looming KEYTRUDA exclusivity loss. Over a longer five-year period, Merck's total shareholder return, including dividends, increased by 15.68%, providing broader context compared to its recent quarterly performance. However, over the past year, Merck underperformed the US market, which returned 19.4%, highlighting potential areas for growth despite the positive trial results. The promising trial outcomes may positively impact revenue and earnings forecasts, aligning with analysts' assumptions of a 4.3% annual revenue growth over the next three years. If expectations hold, earnings might reach US$24.3 billion by 2028. Such advancements in the oncology segment could be pivotal given the price target of US$100.41. With the current share price at US$80.03, the price target implies a potential increase of 25.5%, assuming other market conditions remain constant. Evaluate Merck's prospects by accessing our earnings growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include MRK. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
an hour ago
- Fox News
FIRST ON FOX: Navy slashes civilian public affairs jobs in push for military readiness
FIRST ON FOX: The Navy is taking bold steps to cut red tape and sharpen its focus on the fight. A new memo signed by Secretary of the Navy John C. Phelan orders a 35% cut to civilian Public Affairs Officer (PAO) billets and moves all hiring and contracting decisions under tighter control. Leaders say the goal is to make the force leaner, faster and more disciplined while saving taxpayer money. "The memo was signed with the intent to make a more lethal and agile force, placing the most capable people in the right positions to support the warfighter," a Navy official told Fox News Digital on background. "It seeks to prioritize warfighting readiness, reinforce standards and discipline, as well as accelerate decision-making." "The Department of the Navy must ensure public affairs resources are aligned to warfighting readiness, standards and discipline, and rapid decision-making," the memo states. From now on, any civilian public affairs hiring must be approved by the Navy's Chief of Information (CHINFO) or the Marine Corps Communications Directorate (CD). Contracts for media and messaging support will also be pooled into one system so commands across the fleet can use the same process. The memo directs that "civilian public affairs billets in headquarters, staff support, and non-operational environments shall be reduced or eliminated." The changes come after a review found the civilian public affairs workforce had grown far beyond what was needed. The study flagged overlapping jobs, inconsistent messaging and inefficient spending. Navy leaders say the overhaul will not only trim costs, but also ensure that every communication effort supports readiness and the men and women on the front lines. The Marine Corps is not included in the cuts because it is already going through a separate review. For the Navy, the memo notes that "some billets may be realigned to active-duty or reserve Public Affairs Officers," putting more uniformed leaders in charge of telling the Navy's story. The directive also requires CHINFO and CD to "document projected cost savings and assess opportunities to reinvest in fleet support and uniformed public affairs capacity." "This is about discipline, efficiency and lethality," a senior Navy official told Fox News Digital. "Every resource we save here is a resource we can put back into readiness and the fight."
